Longjumeau, 24 January 2013
Net sales up 5.9% in 2012
(in thousands of euros) | 2010 | 2011 | 2012 | % change |
Total as of 31 December | 158 511 | 164 544 | 174 289 | 5,9% |
including Pharmaceutical Synthesis | 99 379 | 102 096 | 110 001 | 7,7% |
including Fine Speciality Chemicals | 59 132 | 62 448 | 64 288 | 2,9% |
The Dynaction Group achieved 5.9% growth in consolidated net sales for 2012 compared with 2011.
Pharmaceutical Synthesis
Net sales are up 7.7% for 2012 compared with 2011, driven by activities based on proprietary technological platforms.
Fine Specialty Chemicals
The Fine Specialty Chemicals business has continued to grow (+2.9% in 2012 versus 2011), despite confirmation of the Fragrance business underperforming.
In view of this increase in sales, it is possible, as of now, to confirm a significant growth in current operating income for 2012 in relation to 2011.
Next date: 2012 results on 20 February 2013
About Dynaction :
Dynaction is an industrial holding company focused on a unique development pole: Fine Speciality Chemicals, a field of its subsidiary PCAS and in which it holds a majority share of 60.94 %.
http://hugin.info/143387/R/1673040/544537.pdf
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: DYNACTION via Thomson Reuters ONE